Moreover, the use of JAK inhibitors to abrogate the IFN signal in patients also improve the clinical symptoms in patients suffering from juvenile dermatomyositis, Still ́s disease, CANDLE, SAVI, and other interferonopathies (30–32), suggesting that the discovery of new compounds that limit the expression of IFN would be of direct interest for the prevention of the global phenotype, including neurological alterations. This evidence concerns the gene IFNA1 and juvenile dermatomyositis.